176 related articles for article (PubMed ID: 35363892)
41. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
42. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.
Li Y; Zhu S; Liu W; Ming J; Wang X; Hu X
Ann Hematol; 2020 Jun; 99(6):1161-1176. PubMed ID: 32333155
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F; Ross DM; Radinoff A; Palandri F; Myasnikov A; Vannucchi AM; Zachee P; Gisslinger H; Komatsu N; Foltz L; Mannelli F; Passamonti F; Gilotti G; Sadek I; Tiwari R; Zor E; Al-Ali HK
Leukemia; 2021 Dec; 35(12):3455-3465. PubMed ID: 34017073
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
47. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
48. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Tiribelli M; Benevolo G; Martino B; Abruzzese E; D'Adda M; Polverelli N; Bergamaschi M; Tieghi A; Cavazzini F; Ibatici A; Crugnola M; Bosi C; Latagliata R; Di Veroli A; Scaffidi L; de Marchi F; Cerqui E; Anaclerico B; De Matteis G; Spinsanti M; Sabattini E; Catani L; Aversa F; Di Raimondo F; Vitolo U; Lemoli RM; Fanin R; Merli F; Russo D; Cuneo A; Bacchi Reggiani ML; Cavo M; Vianelli N; Breccia M
Oncotarget; 2017 Oct; 8(45):79073-79086. PubMed ID: 29108288
[TBL] [Abstract][Full Text] [Related]
49. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
Oritani K; Ohishi K; Okamoto S; Kirito K; Komatsu N; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Okada H; Amagasaki T; Wakase S; Shimozuma K; Akashi K
Curr Med Res Opin; 2018 Mar; 34(3):531-537. PubMed ID: 29224367
[TBL] [Abstract][Full Text] [Related]
50. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
51. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
52. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
53. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
54. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
[TBL] [Abstract][Full Text] [Related]
55. The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.
Barone M; Catani L; Ricci F; Romano M; Forte D; Auteri G; Bartoletti D; Ottaviani E; Tazzari PL; Vianelli N; Cavo M; Palandri F
Oncoimmunology; 2020 Jun; 9(1):1782575. PubMed ID: 32923146
[TBL] [Abstract][Full Text] [Related]
56. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Coltro G; Sant'Antonio E; Palumbo GA; Mannelli F; De Stefano V; Ruggeri M; Elli EM; Zanotti R; Borsani O; Bertozzi I; Duminuco A; Betti S; Carli G; Cavalca F; Tanasi I; Rumi E; Randi ML; Garibaldi B; Loscocco GG; Guglielmelli P; Vannucchi AM
Cancer Med; 2023 Apr; 12(7):8166-8171. PubMed ID: 36708083
[TBL] [Abstract][Full Text] [Related]
57. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
58. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
Tefferi A; Pardanani A
Mayo Clin Proc; 2011 Dec; 86(12):1188-91. PubMed ID: 22034658
[TBL] [Abstract][Full Text] [Related]
59. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528
[TBL] [Abstract][Full Text] [Related]
60. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
